Efracea

Indications

For the reduction of papulopustular lesions in adult patients with facial rosacea

Sizes Available

Efracea contains doxycycline, an antibacterial that has been shown to inhibit neutrophil activity and several pro-inflammatory reactions, including those associated with phospholipase A2, endogenous nitric oxide and interleukin-6. It works by altering the pathophysiology of the inflammatory lesions of rosacea that is, in part, a manifestation of a neutrophil-mediated process. The OD 40mg modified release is designed to stay below the antimicrobial threshold to reduce commonly occurring side effects, while retaining an anti-inflammatory action

More on: Topical acne treatments